A receptor tyrosine kinase network composed of fibroblast growth factor receptors, epidermal growth factor receptor, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, and hepatocyte growth factor receptor drives growth and survival of head and neck squamous carcinoma cell lines

Katherine R. Singleton, Jihye Kim, Trista K. Hinz, Lindsay A. Marek, Matias Casás-Selves, Clark Hatheway, Aik-Choon Tan, James DeGregori, Lynn E. Heasley

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Our laboratory has previously shown that some gefitinibinsensitive head and neck squamous cell carcinoma (HNSCC) cell lines exhibit dominant autocrine fibroblast growth factor receptor (FGFR) signaling. Herein, we deployed a wholegenome loss-of-function screen to identify genes whose knockdown potentiated the inhibitory effect of the FGFR inhibitor, AZ8010, in HNSCC cell lines. Three HNSCC cell lines expressing a genome-wide small hairpin RNA (shRNA) library were treated with AZ8010 and the abundance of shRNA sequences was assessed by deep sequencing. Underrepresented shRNAs in treated cells are expected to target genes important for survival with AZ8010 treatment. Synthetic lethal hits were validated with specific inhibitors and independent shRNAs. We found that multiple alternate receptors provided protection from FGFR inhibition, including receptor tyrosine kinases (RTKs), v-erb-b2 erythroblastic leukemia viral oncogene homolog 2 (ERBB2), and hepatocyte growth factor receptor (MET). We showed that specific knockdown of either ERBB2 or MET in combination with FGFR inhibition led to increased inhibition of growth relative to FGFR tyrosine kinase inhibitor (TKI) treatment alone. These results were confirmed using specific small molecule inhibitors of either ERBB family members or MET. Moreover, the triple combination of FGFR, MET, and ERBB family inhibitors showed the largest inhibition of growth and induction of apoptosis compared with the double combinations. These results reveal a role for alternate RTKs in maintaining progrowth and survival signaling in HNSCC cells in the setting of FGFR inhibition. Thus, improved therapies for HNSCC patients could involve rationally designed combinations of TKIs targeting FGFR, ERBB family members, and MET. Copyright.

Original languageEnglish
Pages (from-to)882-893
Number of pages12
JournalMolecular Pharmacology
Volume83
Issue number4
DOIs
Publication statusPublished - 2013 Apr 1
Externally publishedYes

Fingerprint

Proto-Oncogene Proteins c-met
Fibroblast Growth Factor Receptors
Receptor Protein-Tyrosine Kinases
Oncogenes
Epidermal Growth Factor Receptor
Squamous Cell Carcinoma
Leukemia
Neck
Head
Cell Line
Growth
Small Interfering RNA
Gene Knockdown Techniques
High-Throughput Nucleotide Sequencing
Survival
Drive
Protein-Tyrosine Kinases
Therapeutics
Inhibition (Psychology)
Carcinoma, squamous cell of head and neck

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

A receptor tyrosine kinase network composed of fibroblast growth factor receptors, epidermal growth factor receptor, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, and hepatocyte growth factor receptor drives growth and survival of head and neck squamous carcinoma cell lines. / Singleton, Katherine R.; Kim, Jihye; Hinz, Trista K.; Marek, Lindsay A.; Casás-Selves, Matias; Hatheway, Clark; Tan, Aik-Choon; DeGregori, James; Heasley, Lynn E.

In: Molecular Pharmacology, Vol. 83, No. 4, 01.04.2013, p. 882-893.

Research output: Contribution to journalArticle

Singleton, Katherine R. ; Kim, Jihye ; Hinz, Trista K. ; Marek, Lindsay A. ; Casás-Selves, Matias ; Hatheway, Clark ; Tan, Aik-Choon ; DeGregori, James ; Heasley, Lynn E. / A receptor tyrosine kinase network composed of fibroblast growth factor receptors, epidermal growth factor receptor, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, and hepatocyte growth factor receptor drives growth and survival of head and neck squamous carcinoma cell lines. In: Molecular Pharmacology. 2013 ; Vol. 83, No. 4. pp. 882-893.
@article{0fae85c9d68e45398b1dcf6d7cce2bc1,
title = "A receptor tyrosine kinase network composed of fibroblast growth factor receptors, epidermal growth factor receptor, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, and hepatocyte growth factor receptor drives growth and survival of head and neck squamous carcinoma cell lines",
abstract = "Our laboratory has previously shown that some gefitinibinsensitive head and neck squamous cell carcinoma (HNSCC) cell lines exhibit dominant autocrine fibroblast growth factor receptor (FGFR) signaling. Herein, we deployed a wholegenome loss-of-function screen to identify genes whose knockdown potentiated the inhibitory effect of the FGFR inhibitor, AZ8010, in HNSCC cell lines. Three HNSCC cell lines expressing a genome-wide small hairpin RNA (shRNA) library were treated with AZ8010 and the abundance of shRNA sequences was assessed by deep sequencing. Underrepresented shRNAs in treated cells are expected to target genes important for survival with AZ8010 treatment. Synthetic lethal hits were validated with specific inhibitors and independent shRNAs. We found that multiple alternate receptors provided protection from FGFR inhibition, including receptor tyrosine kinases (RTKs), v-erb-b2 erythroblastic leukemia viral oncogene homolog 2 (ERBB2), and hepatocyte growth factor receptor (MET). We showed that specific knockdown of either ERBB2 or MET in combination with FGFR inhibition led to increased inhibition of growth relative to FGFR tyrosine kinase inhibitor (TKI) treatment alone. These results were confirmed using specific small molecule inhibitors of either ERBB family members or MET. Moreover, the triple combination of FGFR, MET, and ERBB family inhibitors showed the largest inhibition of growth and induction of apoptosis compared with the double combinations. These results reveal a role for alternate RTKs in maintaining progrowth and survival signaling in HNSCC cells in the setting of FGFR inhibition. Thus, improved therapies for HNSCC patients could involve rationally designed combinations of TKIs targeting FGFR, ERBB family members, and MET. Copyright.",
author = "Singleton, {Katherine R.} and Jihye Kim and Hinz, {Trista K.} and Marek, {Lindsay A.} and Matias Cas{\'a}s-Selves and Clark Hatheway and Aik-Choon Tan and James DeGregori and Heasley, {Lynn E.}",
year = "2013",
month = "4",
day = "1",
doi = "10.1124/mol.112.084111",
language = "English",
volume = "83",
pages = "882--893",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "4",

}

TY - JOUR

T1 - A receptor tyrosine kinase network composed of fibroblast growth factor receptors, epidermal growth factor receptor, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, and hepatocyte growth factor receptor drives growth and survival of head and neck squamous carcinoma cell lines

AU - Singleton, Katherine R.

AU - Kim, Jihye

AU - Hinz, Trista K.

AU - Marek, Lindsay A.

AU - Casás-Selves, Matias

AU - Hatheway, Clark

AU - Tan, Aik-Choon

AU - DeGregori, James

AU - Heasley, Lynn E.

PY - 2013/4/1

Y1 - 2013/4/1

N2 - Our laboratory has previously shown that some gefitinibinsensitive head and neck squamous cell carcinoma (HNSCC) cell lines exhibit dominant autocrine fibroblast growth factor receptor (FGFR) signaling. Herein, we deployed a wholegenome loss-of-function screen to identify genes whose knockdown potentiated the inhibitory effect of the FGFR inhibitor, AZ8010, in HNSCC cell lines. Three HNSCC cell lines expressing a genome-wide small hairpin RNA (shRNA) library were treated with AZ8010 and the abundance of shRNA sequences was assessed by deep sequencing. Underrepresented shRNAs in treated cells are expected to target genes important for survival with AZ8010 treatment. Synthetic lethal hits were validated with specific inhibitors and independent shRNAs. We found that multiple alternate receptors provided protection from FGFR inhibition, including receptor tyrosine kinases (RTKs), v-erb-b2 erythroblastic leukemia viral oncogene homolog 2 (ERBB2), and hepatocyte growth factor receptor (MET). We showed that specific knockdown of either ERBB2 or MET in combination with FGFR inhibition led to increased inhibition of growth relative to FGFR tyrosine kinase inhibitor (TKI) treatment alone. These results were confirmed using specific small molecule inhibitors of either ERBB family members or MET. Moreover, the triple combination of FGFR, MET, and ERBB family inhibitors showed the largest inhibition of growth and induction of apoptosis compared with the double combinations. These results reveal a role for alternate RTKs in maintaining progrowth and survival signaling in HNSCC cells in the setting of FGFR inhibition. Thus, improved therapies for HNSCC patients could involve rationally designed combinations of TKIs targeting FGFR, ERBB family members, and MET. Copyright.

AB - Our laboratory has previously shown that some gefitinibinsensitive head and neck squamous cell carcinoma (HNSCC) cell lines exhibit dominant autocrine fibroblast growth factor receptor (FGFR) signaling. Herein, we deployed a wholegenome loss-of-function screen to identify genes whose knockdown potentiated the inhibitory effect of the FGFR inhibitor, AZ8010, in HNSCC cell lines. Three HNSCC cell lines expressing a genome-wide small hairpin RNA (shRNA) library were treated with AZ8010 and the abundance of shRNA sequences was assessed by deep sequencing. Underrepresented shRNAs in treated cells are expected to target genes important for survival with AZ8010 treatment. Synthetic lethal hits were validated with specific inhibitors and independent shRNAs. We found that multiple alternate receptors provided protection from FGFR inhibition, including receptor tyrosine kinases (RTKs), v-erb-b2 erythroblastic leukemia viral oncogene homolog 2 (ERBB2), and hepatocyte growth factor receptor (MET). We showed that specific knockdown of either ERBB2 or MET in combination with FGFR inhibition led to increased inhibition of growth relative to FGFR tyrosine kinase inhibitor (TKI) treatment alone. These results were confirmed using specific small molecule inhibitors of either ERBB family members or MET. Moreover, the triple combination of FGFR, MET, and ERBB family inhibitors showed the largest inhibition of growth and induction of apoptosis compared with the double combinations. These results reveal a role for alternate RTKs in maintaining progrowth and survival signaling in HNSCC cells in the setting of FGFR inhibition. Thus, improved therapies for HNSCC patients could involve rationally designed combinations of TKIs targeting FGFR, ERBB family members, and MET. Copyright.

UR - http://www.scopus.com/inward/record.url?scp=84875438921&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875438921&partnerID=8YFLogxK

U2 - 10.1124/mol.112.084111

DO - 10.1124/mol.112.084111

M3 - Article

C2 - 23371912

AN - SCOPUS:84875438921

VL - 83

SP - 882

EP - 893

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 4

ER -